ALLO Goes WildOne of my waiting list stock can be going wild.
EMA 50 is being tested.
Signal on P10 Extreme Value Sniper
Signal on Cycle Sniper
Green Horizontal Lines are the targets
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−1.56 USD
−327.26 M USD
95.00 K USD
138.57 M
About Allogene Therapeutics, Inc.
Sector
Industry
CEO
David D. Chang
Website
Headquarters
South San Francisco
Founded
2017
FIGI
BBG00KHRRDX3
Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.
$ALLO - Looks good this weekNASDAQ:ALLO - Looks good this week
Weekly momentum and fundamentals are good ...
Good Luck !
ALLO - short squeeze candidate This is not a financial advice!
SL under 4.4
1 TP 6.3
2 TP 8.0
3 TP 10
Only 82.54M float
49.68 short float
Most info on the chart.
Trade carefully!
Buy Opportunity in ALLOThis company is oversold in 1 Hr and $ Hrs charts. It show as bottom fishing opportunity in my Rader.
Please check other signals I released so far.
ALLOALLO Long🚀📊
PLEASE WAIT FOR ENTERING POINT
It is not financial advice. This is my opinion. Please check yourselves and invest in the symbols that you think have a huge potential to reach the best results.
please leave us your opinion and reviews.🙏
Good Luck 👍
ALLOLONG-TERM: Bullish gartley with the PCZ at an iceline, classic bullish divergence on daily/weekly. (not financial advice)
ALLO Long part 2There was a slight change in the markup. The goals remained the same. Medium-term 41-46$
See all ideas
An aggregate view of professional's ratings.
Displays a symbol's price movements over previous years to identify recurring trends.
Curated watchlists where ALLO is featured.
Frequently Asked Questions
The current price of ALLO is 3.01 USD — it has decreased by −3.45% in the past 24 hours. Watch Allogene Therapeutics, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Allogene Therapeutics, Inc. stocks are traded under the ticker ALLO.
ALLO stock has risen by 19.84% compared to the previous week, the month change is a 12.41% rise, over the last year Allogene Therapeutics, Inc. has showed a 19.25% increase.
We've gathered analysts' opinions on Allogene Therapeutics, Inc. future price: according to them, ALLO price has a max estimate of 14.00 USD and a min estimate of 3.50 USD. Watch ALLO chart and read a more detailed Allogene Therapeutics, Inc. stock forecast: see what analysts think of Allogene Therapeutics, Inc. and suggest that you do with its stocks.
ALLO reached its all-time high on May 26, 2020 with the price of 55.00 USD, and its all-time low was 2.01 USD and was reached on Jul 5, 2024. View more price dynamics on ALLO chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
ALLO stock is 6.18% volatile and has beta coefficient of 1.99. Track Allogene Therapeutics, Inc. stock price on the chart and check out the list of the most volatile stocks — is Allogene Therapeutics, Inc. there?
Today Allogene Therapeutics, Inc. has the market capitalization of 645.79 M, it has increased by 4.71% over the last week.
Yes, you can track Allogene Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
Allogene Therapeutics, Inc. is going to release the next earnings report on Feb 26, 2025. Keep track of upcoming events with our Earnings Calendar.
ALLO earnings for the last quarter are −0.32 USD per share, whereas the estimation was −0.33 USD resulting in a 3.83% surprise. The estimated earnings for the next quarter are −0.33 USD per share. See more details about Allogene Therapeutics, Inc. earnings.
Allogene Therapeutics, Inc. revenue for the last quarter amounts to 0.00 USD, despite the estimated figure of 10.77 K USD. In the next quarter, revenue is expected to reach 14.53 K USD.
ALLO net income for the last quarter is −66.29 M USD, while the quarter before that showed −66.36 M USD of net income which accounts for 0.10% change. Track more Allogene Therapeutics, Inc. financial stats to get the full picture.
No, ALLO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 11, 2024, the company has 233.00 employees. See our rating of the largest employees — is Allogene Therapeutics, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Allogene Therapeutics, Inc. EBITDA is −254.97 M USD, and current EBITDA margin is −316.10 K%. See more stats in Allogene Therapeutics, Inc. financial statements.
Like other stocks, ALLO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Allogene Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Allogene Therapeutics, Inc. technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Allogene Therapeutics, Inc. stock shows the sell signal. See more of Allogene Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.